BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27234729)

  • 21. The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation.
    Calp-Inal S; Ajaimy M; Melamed ML; Savchik C; Masiakos P; Colovai A; Akalin E
    Kidney Int; 2016 Jan; 89(1):209-16. PubMed ID: 26535999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal Transplant Patients Biopsied for Cause and Tested for C4d, DSA, and IgG Subclasses and C1q: Which Humoral Markers Improve Diagnosis and Outcomes?
    Cicciarelli JC; Lemp NA; Chang Y; Koss M; Hacke K; Kasahara N; Burns KM; Min DI; Naraghi R; Shah T
    J Immunol Res; 2017; 2017():1652931. PubMed ID: 28182088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients.
    Schaefer SM; Süsal C; Opelz G; Döhler B; Becker LE; Klein K; Sickmüller S; Waldherr R; Macher-Goeppinger S; Schemmer P; Beimler J; Zeier M; Morath C
    HLA; 2016 Feb; 87(2):89-99. PubMed ID: 26840927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Immunol; 2015 Mar; 32(2):66-71. PubMed ID: 25661873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-transplant development of C1q-positive HLA antibodies and kidney graft survival.
    Piazza A; Poggi E; Ozzella G; Adorno D
    Clin Transpl; 2013; ():367-75. PubMed ID: 25095531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies.
    Kim JJ; Shaw O; Martin C; Michaelides G; Balasubramaniam R; Sebire NJ; Mamode N; Dorling A; Vaughan R; Marks SD
    Pediatr Nephrol; 2018 Jan; 33(1):167-174. PubMed ID: 28918487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinically-relevant threshold of preformed donor-specific anti-HLA antibodies in kidney transplantation.
    Salvadé I; Aubert V; Venetz JP; Golshayan D; Saouli AC; Matter M; Rotman S; Pantaleo G; Pascual M
    Hum Immunol; 2016 Jun; 77(6):483-9. PubMed ID: 27085791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation.
    Bamoulid J; Roodenburg A; Staeck O; Wu K; Rudolph B; Brakemeier S; Halleck F; Lehner L; Schönemann C; Lachmann N; Budde K
    Transplantation; 2017 Sep; 101(9):2165-2174. PubMed ID: 27653301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection.
    Cai J; Terasaki PI; Zhu D; Lachmann N; Schönemann C; Everly MJ; Qing X
    Exp Mol Pathol; 2016 Feb; 100(1):45-50. PubMed ID: 26615783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation.
    Ciurea SO; Thall PF; Milton DR; Barnes TH; Kongtim P; Carmazzi Y; López AA; Yap DY; Popat U; Rondon G; Lichtiger B; Aung F; Afshar-Kharghan V; Ma Q; Fernández-Viña M; Champlin RE; Cao K
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1392-8. PubMed ID: 25985919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study.
    Eskandary F; Bond G; Kozakowski N; Regele H; Marinova L; Wahrmann M; Kikić Ž; Haslacher H; Rasoul-Rockenschaub S; Kaltenecker CC; König F; Hidalgo LG; Oberbauer R; Halloran PF; Böhmig GA
    Transplantation; 2017 Mar; 101(3):631-641. PubMed ID: 27120452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
    Zhang Q; Hickey M; Drogalis-Kim D; Zheng Y; Gjertson D; Cadeiras M; Khuu T; Baas AS; Depasquale EC; Halnon NJ; Perens G; Alejos J; Cruz D; Ali N; Shemin R; Kwon M; Fishbein MC; Ardehali A; Deng M; Reed EF
    Transplantation; 2018 Oct; 102(10):e431-e438. PubMed ID: 29916988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-transplant donor specific antibody and its clinical significance in kidney transplantation.
    Thammanichanond D; Ingsathit A; Mongkolsuk T; Rattanasiri S; Kantachuvesiri S; Sakhonrat C; Leenanupan C; Worawichawongs S; Kitpoka P
    Asian Pac J Allergy Immunol; 2012 Mar; 30(1):48-54. PubMed ID: 22523907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival.
    Guidicelli G; Guerville F; Lepreux S; Wiebe C; Thaunat O; Dubois V; Visentin J; Bachelet T; Morelon E; Nickerson P; Merville P; Taupin JL; Couzi L
    J Am Soc Nephrol; 2016 Feb; 27(2):615-25. PubMed ID: 26047793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison Between Total IgG, C1q, and C3d Single Antigen Bead Assays in Detecting Class I Complement-Binding Anti-HLA Antibodies.
    Moreno Gonzales MA; Mitema DG; Smith BH; Schinstock CA; Stegall MD; Wakefield LL; Henderson NA; DeGoey SR; Kreuter JD; Gandhi MJ
    Transplant Proc; 2017 Nov; 49(9):2031-2035. PubMed ID: 29149956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
    Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
    Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donor-specific B Cell Memory in Alloimmunized Kidney Transplant Recipients: First Clinical Application of a Novel Method.
    Wehmeier C; Karahan GE; Krop J; de Vaal Y; Langerak-Langerak J; Binet I; Schaub S; Roelen DL; Claas FHJ; Heidt S;
    Transplantation; 2020 May; 104(5):1026-1032. PubMed ID: 31397804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss.
    Sicard A; Ducreux S; Rabeyrin M; Couzi L; McGregor B; Badet L; Scoazec JY; Bachelet T; Lepreux S; Visentin J; Merville P; Fremeaux-Bacchi V; Morelon E; Taupin JL; Dubois V; Thaunat O
    J Am Soc Nephrol; 2015 Feb; 26(2):457-67. PubMed ID: 25125383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.